Avadel Pharmaceuticals PLC’s Post

View organization page for Avadel Pharmaceuticals PLC, graphic

16,480 followers

We’re pleased to share that the first patient has been dosed in REVITALYZ™, a Phase 3 clinical trial evaluating the safety and efficacy of a potential treatment for idiopathic hypersomnia (IH), a sleep disorder characterized by excessive sleep and daytime sleepiness.    “We are committed to advancing this trial and are emboldened by the excitement of experienced clinical trial sites’ participation, which reflects the critical unmet need in the current landscape.” - Jennifer Gudeman Learn more: https://lnkd.in/gMpNkZBK

  • No alternative text description for this image

So excited to hear this! Once-nightly dosing of sodium oxybate is such a fabulous opportunity for folks with IH.

Like
Reply
Quinn Eastman

Science Writer/Editor at Emory University School of Medicine

2mo

This is good news

Like
Reply

I am so excited to hear this!!!

Like
Reply
See more comments

To view or add a comment, sign in

Explore topics